Clinical Trial Update: EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating locoregional EGFR806-specific CAR T cells for EGFR-positive pediatric CNS tumors. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Teratoid Rhabdoid Tumor
• Choroid Plexus Carcinoma
• Ependymoma
• Germ Cell Tumor
• Glioma
• Medulloblastoma
• Pineoblastoma
• Primitive Neuroectodermal Tumor

Drugs mentioned

• EGFR806-specific CAR T Cell Therapy (EGFR806-targeted chimeric antigen receptor T cell)

Snippet

Sponsor: Seattle Children's Hospital | Conditions: Central Nervous System Tumor, Pediatric, Glioma | Phase 1 | Status: COMPLETED